- Molecular NamePirbuterol
- SynonymPirbuterol hydrochloride; Pirbuterolum [inn-latin]
- Weight240.303
- Drugbank_IDDB01291
- ACS_NO38029-10-6
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-0.39
- pkaN/A
- LogD (pH=7, predicted)-0.66
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-0.11
- LogSw (predicted, AB/LogsW2.0)173.12
- Sw (mg/ml) (predicted, ACD/Labs)14.08
- No.of HBond Donors4
- No.of HBond Acceptors5
- No.of Rotatable Bonds5
- TPSA85.61
- StatusFDA approved
- AdministrationInhalational
- PharmacologyA beta-2 adrenergic bronchodilator used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler ("autohaler").
- Absorption_value60.0
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmA mean of 51 % of the dose is recovered in urine as pirbuterol plus its sulfate conjugate following administration by aerosol. Pirbuterol is not metabolized by catechol-o-methyltransferase. The percent of administered dose recovered as pirbuterol plus its sulfate conjugate does not change significantly over the dose range of 400 mcg to 800 mcg and is not significantly different from that after oral administration of pirbuterol. The plasma half-life measured after oral administration is about two hours.
- Half lifeN/A
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityAdverse effects reported with frequency more than 1% include: nervousness (6.9%), tremor (6.0%), headache (2.0%), dizziness (1.2%), palpitations (1.7%), tachycardia (1.2%), cough (1.2%), nausea (1.7%).
- LD50 (rat)N/A
- LD50 (mouse)N/A